DNTH:NASDAQDianthus Therapeutics, Inc. Analysis
Data as of 2026-09-24 - not real-time
$90.71
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
At $90.71, Dianthus Therapeutics, Inc. shows no decisive moving-average alignment, leaving the trend neutral. It has lost 16.4% over the past 30 days. Relative strength is 28.4 — oversold — and the MACD signal is bearish. Watch $89.78 as support and $112.13 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 55.2% above today's level. Revenue is growing at 294.3%.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 39.2%, a beta of 0.89 and a maximum drawdown of 21.8%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 55.2% above today's level. Revenue is growing at 294.3%.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 39.2%, a beta of 0.89 and a maximum drawdown of 21.8%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 2/10.
Top Market Events
On August 4, Dianthus Therapeutics NASDAQ:DNTH reported second-quarter 2026 results alongside a stack of pipeline...NEW YORK and WALTHAM, Mass., Sept. 01, 2026 GLOBE NEWSWIRE -- Dianthus Therapeutics, Inc. Nasdaq: DNTH , a...NEW YORK and WALTHAM, Mass., Sept. 02, 2026 GLOBE NEWSWIRE -- Dianthus Therapeutics, Inc. Nasdaq: DNTH , a...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- RSI at 28.4 signals oversold conditions
- Trading above the 200-day average of 79.52
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- RSI at 28.4 signals oversold conditions
- Trading above the 200-day average of 79.52
- Analyst targets imply +55.2% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Analyst targets imply +55.2% versus the current price
- Negative return on equity of -26.1%
- Revenue growth of +294.3%
Key Metrics & Analysis
Financial Health
Revenue Growth294.30%
P/E Ratio-19.7
ROE-26.06%
ROA-17.69%
Debt/Equity0.11
P/B Ratio4.2
Op. Cash Flow$-155375008
Free Cash Flow$-92210496
Industry P/E30.3
Technical Analysis
TrendNeutral
RSI28.4
Support$89.78
Resistance$112.13
MA 20$104.09
MA 50$106.47
MA 200$79.52
MACDBearish
VolumeIncreasing
Fear & Greed Index93.45
Valuation
Target Price$140.80
Upside/Downside55.22%
GradeFair
TypeGrowth
Risk Assessment
Beta0.89
Volatility39.18%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.